Effect of Anti-Inflammatory Drugs on Clinical Outcomes in Patients With Malignant Pericardial Effusion
- Authors
- Kim, So Ree; Kim, Eun Kyoung; Cho, Jinhyun; Chang, Sung-A; Park, Sung-Ji; Lee, Sang-Chol; Park, Seung Woo
- Issue Date
- Sep-2020
- Publisher
- Elsevier BV
- Keywords
- cancer; colchicine; constrictive pericarditis; pericardial effusion; pericardiocentesis
- Citation
- Journal of the American College of Cardiology, v.76, no.13, pp 1551 - 1561
- Pages
- 11
- Indexed
- SCIE
SCOPUS
- Journal Title
- Journal of the American College of Cardiology
- Volume
- 76
- Number
- 13
- Start Page
- 1551
- End Page
- 1561
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/33594
- DOI
- 10.1016/j.jacc.2020.08.003
- ISSN
- 0735-1097
1558-3597
- Abstract
- Background
Pericardiocentesis (PCC) with extended catheter drainage has become a relatively safe procedure to control pericardial effusion (PE), but little is known about long-term outcomes after PCC in malignant PE.
Objectives
This study evaluated the effects of anti-inflammatory agents on long-term outcomes after effective drainage of PE in active cancer patients.
Methods
From May 2007 to December 2018, 445 patients with malignant PE who underwent echocardiography-guided PCC were enrolled. Clinical, laboratory, echocardiographic and procedural findings, and clinical outcome data were collected. Use of anti-inflammatory agents including colchicine, nonsteroidal anti-inflammatory drugs, or steroids after PCC was also analyzed. Colchicine was administered in a dose of 0.6 mg orally, twice a day for 2 months. The primary outcome was defined as a composite of all-cause death and re-PCC or pericardial window operation due to recurred PE.
Results
The procedure was successful in 97.0% of the cases, with 1 procedure-related death. During the follow-up of 2 years, 26.1% of patients developed recurrent PE, and 46.0% developed constrictive pericarditis. The colchicine treatment group showed a significantly lower risk of composite events (adjusted hazard ratio [aHR]: 0.65; 95% confidence interval [CI]: 0.49 to 0.87; p = 0.003) as well as all-cause death (aHR: 0.60; 95% CI: 0.45 to 0.81; p = 0.001) than did the noncolchicine group. On propensity score matching, colchicine after PCC was consistently associated with a lower composite events (aHR: 0.55; 95% CI: 0.37 to 0.82; p = 0.003).
Conclusions
In cancer patients with malignant PE, PCC with extended drainage can be an appropriate therapeutic option and shows low complication rate. Patients receiving colchicine after successful PCC showed significant improvement in clinical outcome.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Cardiology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.